Bone marrow transplantation (BMT) now constitutes a major therapeutic option in the treatment of cancer patients. Despite increases in the use and success of BMT in many institutions, morbidity and mortality from infection post-transplant remain major problems. The re-establishment of normal T-cell responsiveness is an essential component in the development of resistance to infectious disease following BMT. This is particularly important for dealing with the latent viruses, Cytomegalovirus (CMV) and Epstein Barr Virus (EBV). In the absence of adequate T-cell responsiveness, these viruses are often fatal. Past experiments with a mouse model system for BMT have demonstrated that the patterns of T-cell receptor (TCR) gene rearrangements among developing T-cells in recipient animals are abnormal. Should a similar situation exist among human BMT recipients, the unusual susceptibility of recipients to infection, even in late stages following transplantation, may be explained. The present proposal will examine the regeneration of the TCR repertoire in pediatric cancer patients following BMT. Patients in this study will be recipients of autologous, HLA-matched, or HLA-mismatched marrow, and will differ accordingly in their susceptibility to infectious disease. RNA will be isolated from patient and control peripheral blood leukocytes (PBL) for the preparation of cDNA and analysis by the polymerase chain reaction (PCR), DNA cloning, and DNA sequencing methods. In addition, the TCR repertoire among EBV-specific T-cell clones established from patient and control PBL will be determined. These measures of T-cell quality will be correlated with the establishment of general T-cell function (to be assessed by proliferative responses to superantigens), the patient's ability to combat disease, and the ultimate success of the BMT procedure. The main hypothesis to be tested in this proposal is that the TCR repertoire available to the BMT recipient is abnormally restricted, yielding a qualitative as well as quantitative T-cell immunodeficiency. Information to be gained by the testing of the above hypothesis will be of substantial value, not only as a prognostic measure of BMT success, but as a guide for the development of future treatments aimed at the eradication of fatal infectious disease in BMT patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057419-03
Application #
2098155
Study Section
Pathology B Study Section (PTHB)
Project Start
1992-08-01
Project End
1996-07-31
Budget Start
1994-08-01
Budget End
1996-07-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Sealy, Robert; Zhan, Xiaoyan; Lockey, Timothy D et al. (2009) SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development? Curr HIV Res 7:497-503
Lockey, Timothy D; Zhan, Xiaoyan; Surman, Sherri et al. (2008) Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Front Biosci 13:5916-27
Bonsignori, Mattia; D'Costa, Sybil; Surman, Sherri et al. (2007) A combination of 5-fluorouracil and membrane-bound antibody inhibits B-cell lymphoma growth in a mouse model system. Leuk Lymphoma 48:406-9
Brown, Scott A; Lockey, Timothy D; Slaughter, Clive et al. (2005) T cell epitope ""hotspots"" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometry. AIDS Res Hum Retroviruses 21:165-70
Slobod, Karen S; Coleclough, Chris; Bonsignori, Mattia et al. (2005) HIV vaccine rationale, design and testing. Curr HIV Res 3:107-12
Zhan, Xiaoyan; Martin, Louis N; Slobod, Karen S et al. (2005) Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 23:5306-20
D'Costa, Sybil S; Hurwitz, Julia L (2003) Phytohemagglutinin inhibits lymphoid tumor growth in vitro and in vivo. Leuk Lymphoma 44:1785-91
Zhan, Xiaoyan; Brown, Brita; Slobod, Karen S et al. (2003) Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporine. Transplantation 76:739-40
D'Costa, Sybil; Hurwitz, Julia L (2003) Customized mitogen or antibody treatments enhance the sensitivity of lymphoid tumors to 5-fluorouracil in vitro and in vivo. Leuk Lymphoma 44:841-7
D'Costa, Sybil; Slobod, Karen S; Hurwitz, Julia L (2003) Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth? Leuk Lymphoma 44:139-42

Showing the most recent 10 out of 40 publications